DOGS: Reaction-Driven de novo Design of Bioactive Compounds

被引:165
作者
Hartenfeller, Markus [1 ]
Zettl, Heiko [1 ]
Walter, Miriam [2 ]
Rupp, Matthias [1 ]
Reisen, Felix [1 ]
Proschak, Ewgenij [2 ]
Weggen, Sascha [3 ]
Stark, Holger [2 ]
Schneider, Gisbert [1 ]
机构
[1] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Zurich, Switzerland
[2] Goethe Univ Frankfurt, Inst Pharmaceut Chem, LiFF OSF ZAFES, Frankfurt, Germany
[3] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany
关键词
HISTAMINE H-4 RECEPTOR; DEVELOPMENT KIT CDK; SOURCE [!text type='JAVA']JAVA[!/text] LIBRARY; MOLECULAR SIMILARITY; THROMBIN; INHIBITORS; ANTAGONIST; DISCOVERY; POTENT;
D O I
10.1371/journal.pcbi.1002380
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We present a computational method for the reaction-based de novo design of drug-like molecules. The software DOGS (Design of Genuine Structures) features a ligand-based strategy for automated 'in silico' assembly of potentially novel bioactive compounds. The quality of the designed compounds is assessed by a graph kernel method measuring their similarity to known bioactive reference ligands in terms of structural and pharmacophoric features. We implemented a deterministic compound construction procedure that explicitly considers compound synthesizability, based on a compilation of 25'144 readily available synthetic building blocks and 58 established reaction principles. This enables the software to suggest a synthesis route for each designed compound. Two prospective case studies are presented together with details on the algorithm and its implementation. De novo designed ligand candidates for the human histamine H-4 receptor and gamma-secretase were synthesized as suggested by the software. The computational approach proved to be suitable for scaffold-hopping from known ligands to novel chemotypes, and for generating bioactive molecules with drug-like properties.
引用
收藏
页数:12
相关论文
共 55 条
[21]   RECAP - Retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry [J].
Lewell, XQ ;
Judd, DB ;
Watson, SP ;
Hann, MM .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1998, 38 (03) :511-522
[22]   Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25
[23]  
Mauser H, 2008, CURR OPIN DRUG DISC, V11, P365
[24]  
Menear K, 1999, EXPERT OPIN INV DRUG, V8, P373
[25]   EFFECTS OF E-3123, A NEW PROTEASE INHIBITOR, ON SEVERAL PROTEASE ACTIVITIES AND ON EXPERIMENTAL ACUTE-PANCREATITIS [J].
MIYAMOTO, K ;
HISHINUMA, I ;
NAGAKAWA, J ;
NAGAOKA, N ;
YAMANAKA, T ;
WAKABAYASHI, T .
FOLIA PHARMACOLOGICA JAPONICA, 1988, 91 (05) :285-293
[26]  
Nochi S, 1998, CHEM PHARM BULL, V37, P2855
[27]   Trypsin cleaves exclusively C-terminal to arginine and lysine residues [J].
Olsen, JV ;
Ong, SE ;
Mann, M .
MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (06) :608-614
[28]   Novel thrombin inhibitors incorporating non-basic partially saturated heterobicyclic P1-arginine mimetics [J].
Peterlin-Masic, L ;
Mlinsek, G ;
Solmajer, T ;
Trampus-Bakija, A ;
Stegnar, M ;
Kikelj, D .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (05) :789-794
[29]   MATHEMATICAL BASIS OF RING-FINDING ALGORITHMS IN CIDS [J].
PLOTKIN, M .
JOURNAL OF CHEMICAL DOCUMENTATION, 1971, 11 (01) :60-&
[30]   Feature trees: A new molecular similarity measure based on tree matching [J].
Rarey, M ;
Dixon, JS .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1998, 12 (05) :471-490